These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35170719)

  • 1. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
    Darlow CA; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock LJV; Das S; Hope W
    J Antimicrob Chemother; 2022 Apr; 77(5):1334-1343. PubMed ID: 35170719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings.
    Darlow CA; McEntee L; Johnson A; Farrington N; Unsworth J; Jimenez-Valverde A; Jagota B; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock L; Das S; Hope W
    J Antimicrob Chemother; 2022 Nov; 77(12):3349-3357. PubMed ID: 36177766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
    Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.
    Darlow CA; Hope W
    J Antimicrob Chemother; 2022 Feb; 77(3):711-718. PubMed ID: 34969066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Darlow CA; da Costa RMA; Ellis S; Franceschi F; Sharland M; Piddock L; Das S; Hope W
    Paediatr Drugs; 2021 Sep; 23(5):465-484. PubMed ID: 34435316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis.
    Gastine S; Obiero C; Kane Z; Williams P; Readman J; Murunga S; Thitiri J; Ellis S; Correia E; Nyaoke B; Kipper K; van den Anker J; Sharland M; Berkley JA; Standing JF
    J Antimicrob Chemother; 2022 Feb; 77(2):448-456. PubMed ID: 35107141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
    Obiero CW; Williams P; Murunga S; Thitiri J; Omollo R; Walker AS; Egondi T; Nyaoke B; Correia E; Kane Z; Gastine S; Kipper K; Standing JF; Ellis S; Sharland M; Berkley JA;
    Arch Dis Child; 2022 Sep; 107(9):802-810. PubMed ID: 35078765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
    Darlow CA; Parrott N; Peck RW; Hope W
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):464-475. PubMed ID: 38108548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries.
    Bielicki JA; Sharland M; Heath PT; Walker AS; Agarwal R; Turner P; Cromwell DA
    JAMA Netw Open; 2020 Feb; 3(2):e1921124. PubMed ID: 32049298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection model.
    Garimella N; Zere T; Hartman N; Gandhi A; Bekele A; Li X; Stone H; Sacks L; Weaver JL
    Int J Antimicrob Agents; 2020 Apr; 55(4):105861. PubMed ID: 31838036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.
    Wang J; Zhang H; Yan J; Zhang T
    J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.
    Zhao M; Bulman ZP; Lenhard JR; Satlin MJ; Kreiswirth BN; Walsh TJ; Marrocco A; Bergen PJ; Nation RL; Li J; Zhang J; Tsuji BT
    J Antimicrob Chemother; 2017 Jul; 72(7):1985-1990. PubMed ID: 28444224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.
    Standing JF
    J Antimicrob Chemother; 2022 Jun; 77(7):2046-2047. PubMed ID: 35171988
    [No Abstract]   [Full Text] [Related]  

  • 16. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients.
    Zeitlinger MA; Marsik C; Georgopoulos A; Müller M; Heinz G; Joukhadar C
    Int J Antimicrob Agents; 2003 Jun; 21(6):562-7. PubMed ID: 12791470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response.
    Darlow CA; Hope W
    J Antimicrob Chemother; 2022 Jun; 77(7):2047-2048. PubMed ID: 35243500
    [No Abstract]   [Full Text] [Related]  

  • 18. Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.
    Ortiz Zacarías NV; Dijkmans AC; Burggraaf J; Mouton JW; Wilms EB; van Nieuwkoop C; Touw DJ; Kamerling IMC; Stevens J
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin.
    Nakazawa H; Kikuchi Y; Honda T; Isago T; Nozaki M
    J Infect Chemother; 2003 Dec; 9(4):304-9. PubMed ID: 14691650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli.
    Berleur M; Guérin F; Massias L; Chau F; Poujade J; Cattoir V; Fantin B; de Lastours V
    J Antimicrob Chemother; 2018 Nov; 73(11):3074-3080. PubMed ID: 30085154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.